181 related articles for article (PubMed ID: 1653394)
21. Comparison of a DNA probe assay with the plaque reduction assay for measuring the sensitivity of herpes simplex virus and varicella-zoster virus to penciclovir and acyclovir.
Standring-Cox R; Bacon TH; Howard BA
J Virol Methods; 1996 Jan; 56(1):3-11. PubMed ID: 8690764
[TBL] [Abstract][Full Text] [Related]
22. In vitro selection of drug-resistant varicella-zoster virus (VZV) mutants (OKA strain): differences between acyclovir and penciclovir?
Andrei G; De Clercq E; Snoeck R
Antiviral Res; 2004 Mar; 61(3):181-7. PubMed ID: 15168799
[TBL] [Abstract][Full Text] [Related]
23. Broad-spectrum antiviral activity of the acyclic guanosine phosphonate (R,S)-HPMPG.
Terry BJ; Mazina KE; Tuomari AV; Haffey ML; Hagen M; Feldman A; Slusarchyk WA; Young MG; Zahler R; Field AK
Antiviral Res; 1988 Dec; 10(4-5):235-51. PubMed ID: 2852486
[TBL] [Abstract][Full Text] [Related]
24. Efficacy of oral treatment with BV-araU against cutaneous infection with herpes simplex type 1 in shaved mice.
Machida H; Ijichi K; Takezawa J
Antiviral Res; 1992 Feb; 17(2):133-43. PubMed ID: 1554238
[TBL] [Abstract][Full Text] [Related]
25. Mode of action of (1'S,2'R)-9-[[1',2'-bis(hydroxymethyl) cycloprop-1'-yl]methyl]guanine (A-5021) against herpes simplex virus type 1 and type 2 and varicella-zoster virus.
Ono N; Iwayama S; Suzuki K; Sekiyama T; Nakazawa H; Tsuji T; Okunishi M; Daikoku T; Nishiyama Y
Antimicrob Agents Chemother; 1998 Aug; 42(8):2095-102. PubMed ID: 9687413
[TBL] [Abstract][Full Text] [Related]
26. Comparison of the effects of arabinosyladenine, arabinosylhypoxanthine, and arabinosyladenine 5'-monophosphate against herpes simplex virus, varicella-zoster virus, and cytomegalovirus with their effects on cellular deoxyribonucleic acid synthesis.
Gephart JF; Lerner AM
Antimicrob Agents Chemother; 1981 Jan; 19(1):170-8. PubMed ID: 6166244
[TBL] [Abstract][Full Text] [Related]
27. In vitro antiherpesviral activity of 5-alkyl derivatives of 1-beta-D-arabinofuranosyluracil.
Machida H; Sakata S; Kuninaka A; Yoshino H; Nakayama C; Saneyoshi M
Antimicrob Agents Chemother; 1979 Aug; 16(2):158-63. PubMed ID: 485126
[TBL] [Abstract][Full Text] [Related]
28. Synergistic inhibition of herpesvirus replication by docosanol and antiviral nucleoside analogs.
Marcelletti JF
Antiviral Res; 2002 Nov; 56(2):153-66. PubMed ID: 12367721
[TBL] [Abstract][Full Text] [Related]
29. Comparison of two bromovinyl nucleoside analogs, 1-beta-D-arabinofuranosyl-E-5-(2-bromovinyl)uracil and E-5-(2-bromovinyl)-2'-deoxyuridine, with acyclovir in inhibition of Epstein-Barr virus replication.
Lin JC; Machida H
Antimicrob Agents Chemother; 1988 Jul; 32(7):1068-72. PubMed ID: 2847639
[TBL] [Abstract][Full Text] [Related]
30. Synergistic antiviral activity of acyclovir and vidarabine against herpes simplex virus types 1 and 2 and varicella-zoster virus.
Suzuki M; Okuda T; Shiraki K
Antiviral Res; 2006 Nov; 72(2):157-61. PubMed ID: 16797734
[TBL] [Abstract][Full Text] [Related]
31. [Contribution of the laboratory in case of resistance to acyclovir of herpes simplex and varicella zoster virus].
Morfin F; Frobert E; Thouvenot D
Ann Biol Clin (Paris); 2003; 61(1):33-40. PubMed ID: 12604384
[TBL] [Abstract][Full Text] [Related]
32. Utility of ultra-deep sequencing for detection of varicella-zoster virus antiviral resistance mutations.
Mercier-Darty M; Boutolleau D; Lepeule R; Rodriguez C; Burrel S
Antiviral Res; 2018 Mar; 151():20-23. PubMed ID: 29337163
[TBL] [Abstract][Full Text] [Related]
33. Construction of a herpes simplex virus/varicella-zoster virus (HSV/VZV) thymidine kinase recombinant with the pathogenic potential of HSV and a drug sensitivity profile resembling that of VZV.
Bevilacqua F; Davis-Poynter N; Worrallo J; Gower D; Collins P; Darby G
J Gen Virol; 1995 Aug; 76 ( Pt 8)():1927-35. PubMed ID: 7636473
[TBL] [Abstract][Full Text] [Related]
34. Comparison of antiviral assay methods using cell-free and cell-associated varicella-zoster virus.
Shiraki K; Ochiai H; Namazue J; Okuno T; Ogino S; Hayashi K; Yamanishi K; Takahashi M
Antiviral Res; 1992 Jun; 18(2):209-14. PubMed ID: 1329651
[TBL] [Abstract][Full Text] [Related]
35. Oral bioavailability and anti-simian varicella virus efficacy of 1-beta-D-arabinofuranosyl-E-5-(2-bromovinyl)uracil (BV-araU) in monkeys.
Soike K; Huang JL; Tu JI; Stouffer B; Mitroka JG; Swerdel M; Olsen S; Bonner DP; Tuomari AV; Field AK
J Infect Dis; 1992 Apr; 165(4):732-6. PubMed ID: 1313071
[TBL] [Abstract][Full Text] [Related]
36. Antiherpesviral and anticellular effects of 1-beta-D-arabinofuranosyl-E-5-(2-halogenovinyl) uracils.
Machida H; Sakata S; Kuninaka A; Yoshino H
Antimicrob Agents Chemother; 1981 Jul; 20(1):47-52. PubMed ID: 6269482
[TBL] [Abstract][Full Text] [Related]
37. Effect of ara-T on the replication of herpes simplex virus, varicella-zoster virus and cytomegalovirus.
Miller RL; Iltis JP; Rapp F
IARC Sci Publ (1971); 1978; (24 Pt 2):991-7. PubMed ID: 221418
[TBL] [Abstract][Full Text] [Related]
38. Efficacies of antiherpesvirus nucleosides against two strains of herpes simplex virus type 1 in Vero and human embryo lung fibroblast cells.
Suzutani T; Machida H; Sakuma T
Antimicrob Agents Chemother; 1988 Jul; 32(7):1046-52. PubMed ID: 2847637
[TBL] [Abstract][Full Text] [Related]
39. Synthesis and biological activities of 4-O-(difluoromethyl)-5-substituted-uracil nucleoside analogues.
Reefschläger J; Pein CD; Cech D
J Med Chem; 1988 Feb; 31(2):393-7. PubMed ID: 2828623
[TBL] [Abstract][Full Text] [Related]
40. Antiherpes activity of (E)-5-(2-bromovinyl)- and 5-vinyl-1-beta-D-arabinofuranosyluracil and some other 5-substituted uracil arabinosyl nucleosides in two different cell lines.
Reefschläger J; Herrmann G; Bärwolff D; Schwarz B; Cech D; Langen P
Antiviral Res; 1983 Sep; 3(3):175-87. PubMed ID: 6316849
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
